Clinical study of nimotuzumab combined with concurrent radiochemotherapy for treatment of locally advanced cervical cancer

References

• Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424. doi:10.3322/caac.2149230207593
   PubMed Web of Science ®Google Scholar
• William A, Peters III, Liu PY, et al. Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix. J Clin Oncol. 2000;18:1606–1613. doi:10.1200/JCO.2000.18.10.205910764420
   PubMed Web of Science ®Google Scholar
• Henry M, Bundy BN, Stenman FB, et al. A comparison of weekly cisplatin during radiation therapy versus irradiation alone each followed by adjuvant hysterectomy in bulky stage IB cervical carcinoma: a randomized trial of the Gynecologic Oncology Group. N Engl J Med. 1999;340:1154–1161. doi:10.1056/NEJM19990513340190910202166
   PubMedGoogle Scholar
• Whitney CW, Sause W, Bundy BN, et al. Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stages IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study. J Clin Oncol. 1999;17:1339–1348. doi:10.1200/JCO.1999.17.5.133910334517
   PubMed Web of Science ®Google Scholar
• Eifel PJ, Winter K, Morris M, et al. Pelvic irradiation with concurrent chemotherapy versus pelvic and para-aortic irradiation for high-risk cervical cancer: an update of Radiation Therapy Oncology Group Trial (RTOG) 90-01. J Clin Oncol. 2004;22:872–880. doi:10.1200/JCO.2004.08.04014990643
   PubMed Web of Science ®Google Scholar
• Bellone S, Frera G, Landolfi G, et al. Overexpression of epidermal growth factor type-1 receptor (EGF-Rl) in cervical cancer: implications for Cetuximab-mediated therapy in recurrent/metastatic disease. Gynecol Oncol. 2007;106:513–520. doi:10.1016/j.ygyno.2007.04.02817540437
   PubMed Web of Science ®Google Scholar
• Frobe A, Jones G, Bokulic T, et al. High-dose-rate brachytherapy and concurrent chemo-radiotherapy followed by surgery for stage Ib-IIb cervical institution experience. Anticancer Res. 2014;34:3861–3866.24982415
   PubMed Web of Science ®Google Scholar
• Cetina L, Crombet T, Jiménez-Lima R, et al. A pilot study of nimotuzumab plus single agent chemotherapy as second- or third-line treatment or more in patients with recurrent, persistent or metastatic cervical cancer. Cancer Biol Ther. 2015;16:684–689. doi:10.4161/15384047.2014.98754825802932
   PubMed Web of Science ®Google Scholar
• Gao CZ, Wu XZ, Yan Y, et al. Sensitization of radiation or gemcitabine-based chemoradiation therapeutic effect by nimotuzumab in pancreatic cancer cells. Technol Cancer Res Treat. 2016;15:446–452. doi:10.1177/153303461558520925987640
   PubMed Web of Science ®Google Scholar
• Basavaraj C, Sierra P, Shivu J, Melarkode R, Monte E, Nair P. Nimotuzumab with chemo-radiation confers a survival advantage in treatment-naive head and neck tumors over expressing EGFR. Cancer Biol Ther. 2010;10:673–681. doi:10.4161/cbt.10.8.1291420647773
   PubMed Web of Science ®Google Scholar
• Boland W, Bebb G. The emerging role of nimotuzumab in the treatment of non-small cell lung cancer. Biologics. 2010;4:289–298.21116327
   PubMedGoogle Scholar
• Strumberg D, Schultheis B, Scheulen ME, et al. The emerging role of nimotuzumab in the treatment of non-small cell lung cancer. Invest New Drugs. 2012;30:1138–1143. doi:10.1007/s10637-010-9517-021170759
   PubMed Web of Science ®Google Scholar
• Rodriguez MO, Rivero TC, Bahi RDC, et al. Nimotuzumab plus radiotherapy for unresectable squamous-cell carcinoma of the head and neck. Cancer Biol Ther. 2010;9:343–349. doi:10.4161/cbt.9.5.1098120448462
   PubMed Web of Science ®Google Scholar
• Liu ZG, Zhao Y, Tang J, et al. Nimotuzumab combined with concurrent chemoradiotherapy in locally advanced nasopharyngeal carcinoma: a retrospective analysis. Oncotarget. 2016;7:24429–24435.27016412
   PubMedGoogle Scholar
• Zheng X, Du X. Prognostic significance of EGFR in cervical cancer: a meta-analysis. Ch J Cancer Prev Treat. 2015;22:1321–1327.
   PubMedGoogle Scholar
• Tinker AV, Ellard S, Welch S, et al. Phase II study of temsirolimus (CCI-779) in women with recurrent, unresectable, locally advanced or metastatic carcinoma of the cervix. A trial of the NCIC Clinical Trials Group (NCIC CTG IND 199). Gynecol Oncol. 2013;130:269–274. doi:10.1016/j.ygyno.2013.05.00823672928
   PubMed Web of Science ®Google Scholar
• Rose PG, Blessing JA, Lele S, Lele S, Abulafi O. Evaluation of pegylated liposomal doxorubicin (Doxil) as second-line chemotherapy of squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group. Gynecol Oncol. 2006;102:210–213. doi:10.1016/j.ygyno.2005.11.04816478630
   PubMed Web of Science ®Google Scholar
• Candelaria M, Arias-Bonfill D, Chavez-Blanco A, et al. Lack in efficacy for imatinib mesylate as second-line treatment of recurrent or metastatic cervical cancer expressing platelet-derived growth factor receptor alpha. Int J Gynecol Cancer. 2009;19:1632–1637. doi:10.1111/IGC.0b013e3181a80bb519955950
   PubMed Web of Science ®Google Scholar
• Nogueira‐Rodrigues A, Moralez G, Grazziotin R, et al. Phase 2 trial of erlotinib combined with cisplatin and radiotherapy in patients with locally advanced cervical cancer. Cancer. 2014;120:1187–1193. doi:10.1002/cncr.2847124615735
   PubMed Web of Science ®Google Scholar
• De la Rochefordiere A, Kamal M, Floquet A, et al. PIK3CA pathway mutations predictive of poor response following standard radiochemotherapy ± cetuximab in cervical cancer patients. Clin Cancer Res. 2015;21:2530–2537. doi:10.1158/1078-0432.CCR-14-236825724520
   PubMed Web of Science ®Google Scholar
• Hou MM, Liu X, Wheler J, et al. Targeted PI3K/AKT/mTOR therapy for metastatic carcinomas of the cervix: a phase I clinical experience. Oncotarget. 2014;5:11168. doi:10.18632/oncotarget.258425426553
   PubMedGoogle Scholar
• Assad DX, Elias ST, Melo AC, Ferreira CG, De Luca Canto G, Guerra EN. Potential impact of mTOR inhibitors on cervical squamous cell carcinoma: a systematic review. Oncol Lett. 2016;12:4107–4116. doi:10.3892/ol.2016.515727895779
   PubMed Web of Science ®Google Scholar
• Melo AC, Grazziotin-Reisner R, Erlich F, et al. A phase I study of mTOR inhibitor everolimus in association with cisplatin and radiotherapy for the treatment of locally advanced cervix cancer: PHOENIX. I Cancer Chemother Pharmacol. 2016;78:101–109. doi:10.1007/s00280-016-3064-027206639
   PubMed Web of Science ®Google Scholar
• Frenel JS, Le Tourneau C, O’Neil B, et al. Safety and efficacy of pembrolizumab in advanced, programmed death ligand 1–positive cervical cancer: results from the Phase Ib KEYNOTE-028 Trial. J Clin Oncol. 2017;35:4035–4041. doi:10.1200/JCO.2017.74.547129095678
   PubMed Web of Science ®Google Scholar
• Schellens JHM, Marabelle A, Zeigenfuss S, Ding J, Pruitt SK, Chung HC. Pembrolizumab for previously treated advanced cervical squamous cell cancer: preliminary results from the phase 2 KEYNOTE-158 study. J Clin Oncol. 2017;35:5514. doi:10.1200/JCO.2017.35.15_suppl.5514
   Web of Science ®Google Scholar
• Tian SZ, Wang YX, Tian MY, Cheng. Experimental study on the treatment of cervical cancer with drug resistance by nimotuzumab combined with chemotherapy and radiotherapy. Chin J Cancer Prev Treat. 2017;24:1284–1289.
   Google Scholar
• Lu H, Wu Y, Liu X, et al. A prospective study on neoadjuvant chemoradiotherapy plus anti-EGFR monoclonal antibody followed by surgery for locally advanced cervical cancer. Onco Targets and Ther. 2018;11:3785. doi:10.2147/OTT.S16407129997439
   PubMed Web of Science ®Google Scholar